Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment

Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6. doi: 10.1042/bst0320393.

Abstract

There is extensive evidence from the molecular and genomic analysis of human cancers that the PI 3-kinase (phosphoinositide 3-kinase)-Akt/PKB (protein kinase B) pathway is deregulated in malignant progression. Furthermore, the causal involvement of PI 3-kinase is supported by gene-knockout mouse models. Prototype inhibitors show evidence of anticancer activity in vitro and in vivo animal models. The recent development of isoform-selective inhibitors shows considerable promise for cancer treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Disease Models, Animal
  • Disease Progression
  • Enzyme Inhibitors / therapeutic use
  • Genome
  • Humans
  • Mice
  • Mice, Knockout
  • Models, Chemical
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Phosphoinositide-3 Kinase Inhibitors*
  • Protein Isoforms

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Isoforms